1 Pre-exposure prophylaxis uptake among users of non-occupational post-2 exposure prophylaxis: a longitudinal analysis of attendees at a large sexual health clinic in Montréal 3 4 Authors: Xia, Yiqing MSc<sup>1</sup>; Greenwald, R. Zoë PhD<sup>2, 3</sup>; Milwid, M. Rachael PhD<sup>1</sup>; 5 Trottier, Claire DCS<sup>3</sup>: Boissonnault, Michel MD<sup>3</sup>: Gaul, Neil MD<sup>3</sup>: Charest, Louise MD<sup>3</sup>: 6 Landry, Gabrielle MD<sup>3</sup>: Zahedi, N. Navid MD<sup>3</sup>: Szabo, Jason MD<sup>3,4</sup>: Thomas, Réiean 7 MD<sup>3</sup>: Maheu-Giroux, Mathieu PhD<sup>1</sup> 8 9 **Affiliations:** 10 11 (1) Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montréal, QC, Canada 12 (2) Department of Epidemiology, Dalla Lana School of Public Health, University of 13 Toronto, Toronto, ON, Canada 14 (3) Clinique médicale l'Actuel, Montréal, QC, Canada 15 (4) Centre universitaire de santé McGill (CUSM), Montréal, QC, Canada 16 **Correspondence to:** 17 18 Mathieu Maheu-Giroux, PhD 19 Department of Epidemiology, Biostatistics, and Occupational Health 20 School of Population and Global Health, McGill University 21 1020 Pine Avenue West, Montreal, QC, Canada

40

H3A 1A2 22 23 E-mail: mathieu.maheu-giroux@mcgill.ca Phone: (+1) 514-398-5110 24 25 26 **Conference presentation:** This paper will be presented at the 29<sup>th</sup> Annual Canadian Conference on HIV / AIDS 27 Research; May 2020; Québec city, QC, Canada. 28 Funding: 29 30 This work was supported by the Canadian Foundation for AIDS Research and the 31 Canadian Institutes of Health Research. MM-G's research programs was funded by career awards from the Fonds de recherche du Québec – Santé. 32 **Conflict of Interest Statement:** 33 In the past years l'Actuel PrEP databank has received funding from ViiV Healthcare 34 (2016) and Gilead Sciences Inc. (2018, 2019). L'Actuel PEP databank has received 35 36 funding from ViiV Healthcare (2016). MM-G reports an investigator-sponsored research grant from Gilead Sciences Inc. outside of the submitted work and contractual 37 arrangements from both the World Health Organization and the Joint United Nations 38 39 Programme on HIV/AIDS (UNAIDS), also outside of the submitted work.

Abstract (249 words)

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

**Background**: Reducing HIV transmission using pre-exposure prophylaxis (PrEP) requires targeting individuals at high acquisition risk, such as men who have sex with men (MSM) with a history of non-occupational post-exposure prophylaxis (nPEP). This study aims to characterize longitudinal trends in PrEP uptake and its determinants among nPEP users in Montréal. **Methods**: Eligible attendees at *Clinique médicale l'Actuel* were recruited prospectively starting in October 2000 (nPEP) and January 2013 (PrEP). Linking these cohorts, we characterized the PEP-to-PrEP cascade, examined the determinants of PrEP uptake after nPEP consultation using a Cox proportional-hazard model, and assessed whether PrEP persistence differed by nPEP history using Kaplan-Meier curves. Results: As of August 2019, 31% of 2,682 MSM nPEP cohort participants had two or more nPEP consultations. Subsequent PrEP consultations occurred among 36% of nPEP users, of which 17% sought nPEP again afterwards. Among 2,718 PrEP cohort participants, 46% reported previous nPEP use. Among nPEP users, those aged 25-49 years (Hazard Ratio (HR)=1.3, 95% confidence interval (CI): 1.1-1.7), with more nPEP episodes (HR=1.4, 95%CI: 1.3-1.5), reported chemsex (HR=1.3, 95%CI: 1.1-1.7), with a STI history (HR=1.5; 95%CI: 1.3-1.7), and who returned for their first nPEP follow-up visit (HR=3.4, 95%CI: 2.7-4.2) had higher rates of PrEP linkage. There was no difference in PrEP persistence between PEP-to-PrEP and PrEP only participants. **Conclusion**: Over one-third of nPEP users were subsequently prescribed PrEP. However, the large proportion of men who repeatedly use nPEP calls for more efficient

- 63 PrEP-linkage services and, among those that use PrEP, improved persistence should
- be encouraged.
- 65 **Keywords**: HIV prevention; non-occupational post-exposure prophylaxis (PEP); pre-
- exposure prophylaxis; biomedical prevention; HIV/AIDS; nPEP to PrEP.

# Introduction

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

In 2016, there were an estimated 2,165 new HIV infections in Canada, of which approximately half occurred among gay, bisexual, and other men who have sex with men (gbMSM) [1]. Worldwide, the risk of HIV infection is 27 times higher in gbMSM than the general population [2]. Addressing the unmet prevention needs of key populations at high risk of HIV acquisition and transmission -such as gbMSM- remains a priority. In 2017 Montréal signed the Paris declaration and, shortly after, became the first Canadian city to adopt the UNAIDS Fast-Track City target of zero new HIV infections by 2030 [3]. This ambitious objective will require strengthening the HIV treatment and care cascade and, crucially, must address unmet HIV prevention needs. Non-occupational post-exposure prophylaxis (nPEP) and pre-exposure prophylaxis (PrEP) are two strategies for reducing the risk of HIV acquisition which, when combined with other intervention strategies, could have the potential to achieve HIV elimination [4]. nPEP involves taking a 28-day course of highly active antiretroviral tri-therapy following an event that could carry a moderate/high risk of acquisition (initiated within 72 hours of exposure). It was first implemented following occupational exposure in the early 1990s and was later extended to non-occupational situations such as sexual contacts [5]. In contrast, PrEP was recommended by the World Health Organization in 2012 as a strategy for adults who are at a high, ongoing risk of HIV infection [6]. It can be taken daily, or for gbMSM, intermittently (known as "on demand PrEP") [4 7 8]. Randomized control trials among gbMSM have estimated an overall PrEP effectiveness of 86% [7 9-11] for preventing sexual transmission which could reach 99% for those who are perfectly adherent to treatment guidelines [12].

Contrary to the use of nPEP as an emergency measure, it is recommended that those who seek nPEP repeatedly, or are at an ongoing risk of HIV acquisition, be evaluated for possible PrEP use [13-16]. However, emerging evidence suggests that uptake of PrEP among gbMSM who have repeatedly used nPEP is suboptimal [17]. With the Fast-Track city goal of zero new HIV infections, it is crucial to limit these missed prevention opportunities. In 2013, Québec became the first Canadian province to recommend PrEP and fund it using public budgets. Using 6 years of longitudinal data on sexual health clinic attendees, the overarching aim of this study is to characterize the PEP-to-PrEP corridor and identify potential barriers to linkage. Specifically, we will: 1) describe longitudinal trends in nPEP and PrEP use, 2) estimate the time from nPEP to PrEP and the determinants of PrEP uptake by nPEP users, and 3) compare the differences in PrEP persistence between participants with and without a history of nPEP use. These results could help limit missed HIV prevention opportunities among gbMSM.

## Methods

## Study setting

Clinique médicale l'Actuel (l'Actuel) is a Montréal-based, sexual health clinic specializing in HIV treatment and prevention, predominantly among gbMSM. The clinic is one of the largest nPEP and PrEP providers in Canada and was one of the first clinics to prescribe nPEP (August 2000) and PrEP (January 2013). Attendees at l'Actuel seeking nPEP and PrEP were recruited prospectively from August 2000 for the nPEP cohort and January 2013 for the PrEP cohort. At each nPEP and PrEP consultation, patients complete a questionnaire regarding their demographic and behavioural

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

characteristics and a consent form. The clinical component of the survey is administered by a nurse or physician. Participants consulting for nPEP were scheduled for follow-up visits with a clinician at 4 and 12 weeks following their initial nPEP prescription, which included HIV testing to monitor nPEP efficacy as well as sexual health and HIV prevention counselling, including PrEP referrals when appropriate. All participants consulting for PrEP were scheduled for a follow-up visit 30 days after the baseline consultation and at 3-month intervals thereafter. De-identified questionnaires were then entered into prospective nPEP and PrEP cohort databases. A detailed description of the cohorts and clinical protocols can be found elsewhere [18 19]. Study population The study population included self-identified gbMSM who consulted for nPEP and/or PrEP at Clinique médicale l'Actuel. Participants who were HIV positive at their baseline visit were excluded from the study population. The first analysis assessed longitudinal trends in nPEP and PrEP consultations from October 2000 – August 2019. We restricted the analysis to the time periods during which PrEP was recommended (January 1<sup>st</sup>, 2013 and August 31<sup>st</sup>, 2019) for the primary analysis measuring the determinants of PrEP uptake among nPEP users. Participants were categorized into 4 groups: 1) those who consulted for or received nPEP only (hereafter referred to as PEP only participants), 2) those who consulted for or received PrEP only (hereafter referred to as PrEP only participants), 3) participants who consulted for or received nPEP prior to using PrEP at l'Actuel (hereafter referred to PEP-to-PrEP participants), and 4) PEP-

naïve participants who initiated PrEP and subsequently consulted for nPEP after PrEP

discontinuation (hereafter referred to *PrEP-to-PEP participants*) (**Figure 1**). Our study design enables us to link participants in the nPEP and PrEP cohorts but not those who sought care at other clinics. As such, we could not properly estimate time to linkage, and the small number of participants who sought nPEP at l'Actuel but PrEP elsewhere (N=13) and PrEP at l'Actuel but nPEP from another clinic (N=120) were excluded from the analyses. Participants whose last nPEP consultation took place before 2013 were also excluded from the study regardless of whether they consulted for PrEP as PrEP was unavailable at that time.

## **Analyses**

Longitudinal trends in nPEP and PrEP consultations from 2000-2019 are presented and the demographic and behavioral profiles of "PEP only", "PrEP only", and "PEP-to-PrEP" participants over the 2013-2019 period are compared. The variables examined include: age, education, total number of nPEP episodes, average time between nPEP episodes (for participants who had multiple nPEP episodes and nPEP visits before the first PrEP consultation), adherence to a nPEP treatment (missing <4 pills), early termination of nPEP treatment and whether the participant was re-exposed to HIV during nPEP treatment, chemsex (i.e., sexualized substance use), and a self-reported lifetime history of sexually transmitted infections [17].

The time from the first nPEP visit after 2013 to the first PrEP consultation, stratified by age group (<25, 25-49, ≥50 years, to ensure a large enough sample size in each group while allowing salient age features to be considered), by the total number of nPEP episodes and by the calendar year of the first nPEP visit was explored using Kaplan-

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

Meier curves. Determinants of the time to PrEP uptake among nPEP users were examined using a Cox proportional-hazards model. The model included covariates for which there was previous evidence of potential association [20] or an indication for PrEP [4], including: age and education (secondary and lower, college (including Quebec's Collège d'enseignement général et professionnel (CEGEP) program, university). Additionally, the total number of nPEP episodes, chemsex during the risk episode, self-reported lifetime STI history (any/none) and whether the participants returned for the first nPEP follow-up visit were included in the model and were treated as time-dependent covariates. The year of the first nPEP consult after 2013, was used to stratify the survival analyses. All cohort participants were censored if they seroconverted during follow-up, in August 2019, or at their first PrEP consult, whichever occurred first. Schoenfeld residuals were used to verify that the proportional hazard assumption was met for each predictor-outcome pair [21], while the Efron method was adopted to handle potential ties [22]. Missing values of education (N=325) and STI history (N=91) were handled using multiple imputations and estimates from 5 imputations were pooled using Rubin's rules [23]. Lastly, a Kaplan-Meier analysis was used to characterise the differences in PrEP persistence between PEP-to-PrEP and PrEP only participants who initiated PrEP. PrEP termination was defined as a discontinuation of PrEP as indicated by the participant, or as no active PrEP prescription within the past 6 months after the participant's last PrEP follow-up visit. Participants who consulted for PrEP but who did not attend the first PrEP follow up visit were excluded from the analysis.

All analyses were performed with R version 3.6.1.

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

Ethics approval was obtained through Veritas Institutional Review Board and McGill University. Results Description of the study participants Entire l'Actuel cohort Between October 2000 (for the nPEP cohort) or January 2013 (for the PrEP cohort) and August 2019, 5,512 attendees consulted for nPEP and 3,066 individuals consulted for PrEP at l'Actuel. A total of 6,039 nPEP consultations and 3,253 PrEP consultations took place at l'Actuel among 4.139 and 2.814 gbMSM, respectively. A steady increase in consultations was observed prior to 2016, followed by decreases in both the numbers of nPEP and PrEP consultations from 2017 onwards (Figure 2). The simultaneous reduction in nPEP and PrEP can be explained by the emergence of new clinics specializing in HIV that provide similar services. From January 2013 onwards, of the 2,682 participants who received nPEP and who met the inclusion criteria (i.e., gbMSM, cis-male, consented participation), 36% (972/2,679) also consulted for or received PrEP during that period and only 1% (13/972) reported having had a PrEP consultation outside of l'Actuel. Nearly half of the 2,718 consenting gbMSM PrEP participants also used nPEP during that period (46%, 1,242/2,715), 10% of whom (120/1,242) received nPEP externally to l'Actuel. The majority of participants in both the nPEP and PrEP cohorts consulted for nPEP prior to PrEP (90%, 861/959).

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

Almost all PEP-to-PrEP participants were prescribed PrEP (98%, 847/861) and 17% (144/861) reinitiated nPEP afterwards (Figure 1). Participants included in the main analysis Overall, 1,707 PEP only participants, 861 PEP-to-PrEP participants and 1,473 PrEP only participants were included in the main analyses. More PEP-to-PrEP participants had a history of multiple nPEP episodes than PEP only participants. Furthermore, PEPto-PrEP participants reported a 6-month shorter average time between nPEP episodes than PEP only participants. Approximately 44% (382/861) and 24% (414/1,707) of PEPto-PrEP participants and PEP only participants had at least 2 nPEP episodes. Additionally, the proportion of participants returning for the first nPEP follow-up visit and who were adherent to nPEP treatment was 19% and 12% higher among PEP-to-PrEP participants than PEP only participants. Compared to the other 2 groups, PrEP only participants had a lower education level and the proportion self-reporting a lifetime history of STIs was 10% higher (**Table 1**). Time from nPEP consultation to PrEP uptake and its determinants During the study period, approximately 40% of the nPEP participants linked to PrEP. One quarter of the participants linked to PrEP within the first 20 months after first nPEP consultation. Participants younger than 25 years old had lower rates of PrEP linkage years and participants who had at least 2 nPEP episodes had overall higher rates of PrEP linkage. Participants with more nPEP episodes linked to PrEP at a higher rate. The rate of PrEP linkage increased over time between 2013 and 2019 (Figure 3 A, B, C).

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

Participants aged 25-49 years of age, who had multiple nPEP episodes, chemsex during the risk period, self-reported antecedent STIs, and returned for the first nPEP follow-up visit were the main determinants of time to PrEP linkage in the multivariate model (Table 2). The association between education and PrEP linkage was inconclusive although participants with a university degree had a slightly higher hazard ratio than those who finished college. Estimates of the total number of nPEP episodes suggested that each additional nPEP consultation would increase the rate of PrEP linkage among nPEP users by 39% (HR=1.39, CI: [1.31-1.46]). Chemsex during the risk period and having antecedent STIs increased the rate of PrEP linkage by 30% (HR=1.30, 95% CI: [1.08, 1.56]) and 46% (HR=1.46, 95% CI: [1.26, 1.69]), respectively. Returning for the first nPEP follow-up visit at week 4 was strongly associated with linkage to PrEP, increasing the rate of linkage to 3.36 (95% CI: [2.71, 4.16]) times the rate for those who did not return for the follow-up visit. PrEP persistence among PEP-to-PrEP and PrEP only participants Daily PrEP was prescribed to 78% (674/861) of the PEP-to-PrEP participants and 82% (1,208/1,473) of the *PrEP* only participants while the remainder of the participants were prescribed intermittent PrEP. Following their PrEP consult, 78% of the PEP-to-PrEP participants and 76% of the PrEP only participants initiated PrEP. The probability of PrEP persistence was similar between PEP-to-PrEP and PrEP only participants (Figure 3D). The median time to PrEP discontinuation was 0.59 (95% CI: [0.06, 3.44]) and 0.54 years (95%CI: [0.06, 2.96]) among PEP-to-PrEP and PrEP only participants, respectively. Half of the participants discontinued PrEP within the first year of initiation.

**Discussion** 

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

PrEP is a highly effective biomedical HIV prevention method recommended for high-risk populations, such as gbMSM, and is an important component of combination prevention strategies to achieve HIV elimination [4 6 12]. In our analysis of six years of longitudinal data from the l'Actuel nPEP and PrEP cohorts, approximately 40% of nPEP users were linked to PrEP, of which one quarter of the linkages occurred within the first 20 months after nPEP consultation. nPEP participants aged 25-49 years, who reported multiple nPEP episodes, chemsex, antecedent STIs, and who returned for the first nPEP followup visit were more likely to link to PrEP. Reporting a history of nPEP use did not impact PrEP persistence. Our evaluation suggests that the time from nPEP consult to PrEP linkage rapidly improved over the 2013-2019 period. This was particularly evident after 2015 when more than 20% of individuals consulted for PrEP within the first year of their nPEP consult. A study conducted in Toronto by Siemieniuk et al. (2005) indicated that 10% of the individuals who consulted for nPEP at the HIV Prevention Clinic between 2013 and 2014 initiated PrEP as of 2015 [24]. This proportion is much lower than what was found here- but could be explained by the lack of a publicly funded PrEP program in Ontario at the time. Despite improvements in PEP-to-PrEP linkage at l'Actuel, such progress could be compromised by the overall low persistence on PrEP. Indeed, half of the PrEP users discontinued it during the first year. There are multiple reasons for the observed PrEP discontinuation including: changes in sexual behaviors, such as increased condom use,

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

and the formation of a single long-term partnership [25 26]. However, the discontinuations could be concerning if they are not related to change in sexual behaviors. There is some evidence to suggest that this is not always the case. For example, 98 (7%) PrEP users, and 144 (17%) PEP-to-PrEP users sought nPEP after PrEP discontinuation. If this group is composed of individuals with a low-frequency of high-risk exposures, other interventions such as PIP (post-exposure prophylaxis in pocket) should be considered [27]. This could be important for PEP-experienced users. A recent study in Toronto recorded a high prevalence of syndemic health problems among MSM seeking nPEP [28]. This clustering of syndemic conditions could partly explain low persistence on PrEP of nPEP users, which was also observed in other cohorts [29]. Our results should be interpreted considering several limitations. First, we cannot rule out that participants who used nPEP at l'Actuel eventually consulted for PrEP at other clinics. As such, we may have overestimated time to linkage. Despite this limitation, only 1% of participants in the nPEP cohort reported having taken PrEP outside of l'Actuel. Further, only 10% of the PrEP cohort had consulted for nPEP at another clinic. This could imply that our inability to link our nPEP and PrEP cohorts to other clinics may have only small impacts our inferences. However, given the changing HIV prevention landscape in Montreal after 2017, future work should include multi-sites collaboration. Second, it is difficult to know the exact date of PrEP termination for participants who did not return for a follow-up visit which may result in incorrectly estimating the participants' adherence to a PrEP regimen. The date of last PrEP consultation was used as the end date of PrEP for those who discontinued PrEP, which might underestimate the time on

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

PrEP. Additionally, participants on an intermittent PrEP regime may have sufficient pills to last for more than 6 months, prolonging the time between follow-up visits, which would be treated as "terminated PrEP" in this study and lower the estimated PrEP persistence. However, as the PrEP persistence analysis performed in this study was aimed to observe the difference between PrEP users with and without a nPEP history, this could have minimal impact on our results. Third, and not unlike other studies, we relied on self-reported information regarding potentially sensitive behaviors (e.g., antecedent STI, sexual behaviors, sexualized substance use) that could have been misreported. Finally, the number of missing values for certain covariates was nonnegligible. However, multiple imputation was used which efficiently propagated uncertainty to the relevant effect size measures. As one of the largest nPEP and PrEP providers in Canada, the data collected at Clinique médicale l'Actuel provides a comprehensive data set characterising the trends in nPEP and PrEP use among gbMSM in Montréal. The large sample size of this study enabled us to conduct subgroup analyses. Additionally, the study period covered the time from the beginning of PrEP implementation in Québec until the present which made it possible to capture a complete picture of PrEP use development and the impact of PrEP on nPEP use. These strengths have resulted in a robust quantification of the relationship between nPEP and PrEP use among gbMSM in this Canadian setting. **Conclusions** Making PrEP accessible, and promoting its use, to high risk populations is essential to

prevent HIV transmission. Understanding the current gaps and the determinants of

PEP-to-PrEP linkages could help optimize PrEP delivery. Our results suggest that creating a strong linkage corridor between nPEP and PrEP services could help facilitate PrEP uptake among gbMSM vulnerable to HIV acquisition. Furthermore, given that 17% PEP-to-PrEP users sought nPEP after PrEP discontinuation, future interventions should focus on increasing PrEP continuation among people at on-going HIV risk. These results should be used to better inform individualized HIV prevention strategies if Montréal's Fast-Track city goal of HIV elimination is to be achieved, contributing to the global effort to eliminate HIV/AIDS by 2030 [30].

References

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

1. PHAC. Summary: Estimates of HIV Incidence, Prevalence and Canada's Progress on Meeting the 90-90-90 HIV Targets, 2016, 2018. 2. UNAIDS. Global HIV & AIDS statistics - 2018 fact sheet, 2018. 3. Montréal S. Fast-Track City - A Common Action Plan to Accelerate the Fight Against the HIV/AIDS Epidemic. Secondary Fast-Track City - A Common Action Plan to Accelerate the Fight Against the HIV/AIDS Epidemic 2017. https://santemontreal.gc.ca/en/public/news/news/fast-track-city-a-common-actionplan-to-accelerate-the-fight-against-the-hivaids-epidemic/. 4. Tan DHS, Hull MW, Yoong D, et al. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis. CMAJ 2017;189(47):E1448-E58 doi: 10.1503/cmaj.170494[published Online First: Epub Date]]. 5. WHO. Post-exposure Prophylaxis to Prevent HIV Infection. 2007 6. WHO. Guidance on Pre-exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex With Men at High Risk of HIV, 2012. 7. Molina JM, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New Engl J Med 2015;373(23):2237-46 doi: 10.1056/NEJMoa1506273[published Online First: Epub Date]. 8. Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of ondemand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet Hiv 2017;4(9):E402-E10 doi: 10.1016/S2352-

3018(17)30089-9[published Online First: Epub Date].

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

9. Huang XJ, Hou JH, Song AX, et al. Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol 2018;9 doi: ARTN 79910.3389/fphar.2018.00799[published Online First: Epub Date]|. 10. Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New Engl J Med 2010;363(27):2587-99 doi: 10.1056/NEJMoa1011205[published Online First: Epub Date]. 11. Grohskopf LA, Chillag KL, Gvetadze R, et al. Randomized Trial of Clinical Safety of Daily Oral Tenofovir Disoproxil Fumarate Among HIV-Uninfected Men Who Have Sex With Men in the United States. Jaids-J Acg Imm Def 2013;64(1):79-86 doi: DOI 10.1097/QAI.0b013e31828ece33[published Online First: Epub Date]. 12. CDC. PrEP Brochure. Secondary PrEP Brochure. https://www.cdc.gov/hiv/basics/prep.html. 13. CDC US. PEP 101 Consumer Info Sheet, 2019. 14. CDC USPHS. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2017 Update, 2017. 15. Roland ME, Neilands TB, Krone MR, et al. A Randomized Noninferiority Trial of Standard Versus Enhanced Risk Reduction and Adherence Counseling for Individuals Receiving Post-Exposure Prophylaxis Following Sexual Exposures to HIV. Clin Infect Dis 2011;53(1):76-83 doi: 10.1093/cid/cir333[published Online First: Epub Date]. 16. Whitlock G, McCormack C, Fearnley J, McOwan A. High HIV incidence in men who have sex

with men attending for postexposure prophylaxis: a service evaluation. Sex Transm

362 Infect 2017;93(3) doi: 10.1136/sextrans-2016-052623[published Online First: Epub 363 Date]|. 364 17. Pathela P, Jamison K, Braunstein S, et al. HIV incidence, and pre- and post-exposure 365 prophylaxis (PrEP and PEP) among PEP users at New York city sexual health clinics. Sex 366 Transmitted Infections 2019;95:A203 367 18. Thomas R, Galanakis C, Vezina S, et al. Adherence to Post-Exposure Prophylaxis (PEP) and 368 Incidence of HIV Seroconversion in a Major North American Cohort. Plos One 369 2015;10(11) doi: ARTN e014253410.1371/journal.pone.0142534[published Online First: 370 Epub Date]|. 371 19. Greenwald ZR, Maheu-Giroux M, Szabo J, et al. Cohort profile: l'Actuel Pre-Exposure 372 Prophylaxis (PrEP) Cohort study in Montreal, Canada. BMJ Open 2019;9(6):e028768 doi: 373 10.1136/bmjopen-2018-028768[published Online First: Epub Date] |. 374 20. Greenwald ZR, Beauchemin M, Corsenac P, et al. PrEP initiation following PEP: Creating a 375 Corridor of Care at l'Actuel. CAHR, 2018:51. 376 21. Moore DF. https://doi.org/10.1007/978-3-319-31245-3: Springer, Cham. 377 22. Dohoo I, Martin W, Stryhn H. Veterinary epidemiologic research. Charlottetown, P.E.I.: 378 University of Prince Edward Island, 2003. 379 23. Buuren SV, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in 380 R. Journal of Statistical Software Dec 2011;45(3) 381 24. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, 382 injection-drug use, or other nonoccupational exposure to HIV in the United States:

383 recommendations from the U.S. Department of Health and Human Services. MMWR 384 Recomm Rep 2005;**54**(RR-2):1-20 385 25. Naismith K JT. Washington PrEP DAP Client Survey Key Findings, 2017: Washington State 386 Department of Health Office of Infectious Disease, August 1, 2018. 387 26. Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A. HIV Pre-exposure 388 Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex with Men in a 389 Community-Based Sexual Health Clinic. Aids Behav 2018;22(4):1096-99 doi: 390 10.1007/s10461-017-2009-x[published Online First: Epub Date]|. 391 27. Wood BR. Prevention of HIV for persons with low-frequency, high-risk exposures: PrEP 392 (preexposure prophylaxis), PEP (postexposure prophylaxis), or 'PIP' (postexposure 393 prophylaxis in-pocket). AIDS 2020;**34**(3):481-82 doi: 394 10.1097/QAD.0000000000002446[published Online First: Epub Date]|. 395 28. Morrison SA, Yoong D, Hart TA, et al. High prevalence of syndemic health problems in 396 patients seeking post-exposure prophylaxis for sexual exposures to HIV. Plos One 397 2018;13(5):e0197998 doi: 10.1371/journal.pone.0197998[published Online First: Epub 398 Date]|. 399 29. Zucker J, Carnevale C, Richards P, et al. Predictors of Disengagement in Care for Individuals 400 Receiving Pre-exposure Prophylaxis (PrEP). J Acquir Immune Defic Syndr 401 2019;81(4):e104-e08 doi: 10.1097/QAI.000000000002054[published Online First: Epub 402 Date]|. 30. UNAIDS. Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland: UNAIDS, 2014. 403 404

Figure captions

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

Figure 1 Inclusion and classification of study participants among attendees at the Clinique médicale l'Actuel, Montréal, Canada (October 2000 (PEP) / January 2013 (PrEP) to August 2019). Gay, bisexual, and other men who have sexwith men (gbMSM) participants who only consulted for or received non-occupational post-exposure prophylaxis (PEP) or pre-exposure prophylaxis (PrEP) were defined as "PEP only" and "PrEP only", respectively. Participants who consulted for or received PrEP subsequently to consulting for nPEP were classified as "PEP-to-PrEP". Participants who consulted for or received nPEP after PrEP were defined as "PrEP-to-PEP". Objective 1 includes all participants, Objective 2 (red box) includes PEP only and PEP-to-PrEP participants, and Objective 3 (green box) includes *PrEP only* and *PEP-to-PrEP* participants. Figure 2 Number of post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) consultations conducted among gay, bisexual and other men who have sex with men (gbMSM) between January 2001 and August 2019 at Clinique médicale l'Actuel, Québec (QC), Canada. Each bar represents total number of nPEP consultations during a calendar year with the exception of the last bar which represents an eight-month period. The dashed line represents the total number of PrEP consultations over each time interval between July 2013 and August 2019. nPEP consultations before 2013 are greyed-out to indicate that they occurred before PrEP guidelines came into effect (these were also excluded from subsequent analyses). Figure 3 Survival curves of: (1) The cumulative proportion and 95% confidence intervals for consulting for pre-exposure prophylaxis (PrEP) after a post-exposure

prophylaxis (PEP) consultation stratified by age group (<25, 25-49, and ≥ 50 years) (Panel A), stratified by number of nPEP episodes (1 episode, 2 episodes, and ≥3 episodes) (Panel B), and stratified by calendar year of first nPEP consultation (Panel C), and (2) the proportion of participants who were persistent with pre-exposure prophylaxis (PrEP) stratified by post-exposure prophylaxis (PEP) history (Panel D) at Clinique médicale l'Actuel among gay, bisexual and other men who have sex with men (gbMSM). The x-axis represents the time since first nPEP consultation (Panels A, B, C) or time since first PrEP consultation (Panel D) after 2013 at *Clinique médicale l'Actuel*. PEP-to-PrEP: participants who previously consulted for nPEP and initiated PrEP at *Clinique médicale l'Actuel*. PrEP only: participants who self-reported never having consulted for nPEP (anywhere) but initiated PrEP at *Clinique médicale l'Actuel*.

**Table 1** Demographic and sexual behaviour characteristics of gay, bisexual, and other men who have sex with men (gbMSM) attending *Clinique médicale l'Actuel* at first nPEP consultation or PrEP consultation after 2013 for nPEP *only*, *PEP-to-PrEP*, and *PrEP only* participants.

N (%)	PEP only (N=1,707)	PEP-to-PrEP (N=861)	PrEP only (N=1,473)
Age (mean, SD)	34 (11)	35 (10)	37 (11)
Education			
Secondary and lower	223 (13%)	91 (11%)	204 (14%)
College	358 (21%)	151 (18%)	260 (18 %)
University	924 (54%)	504 (59%)	694 (47%)
Missing	202 (12%)	115 (13%)	315 (21%)
Total number of nPEP episodes (Oct. 2000 to Aug. 2019) <sup>1</sup>			
1 episode	1293 (75%)	479 (56%)	
2 episodes	258 (15%)	192 (22%)	
≥ 3 episodes	156 (9%)	190 (22%)	
Average time between nPEP episodes (months) (mean, SD) <sup>1</sup> (Oct. 2000 to Aug. 2019)	30 (28)	24 (21)	
Chemsex during the risk period related to the consultation	233 (14%)	139 (16%)	
Participated in chemsex in past 12 months			999 (76%)
Lifetime history of STIs (self-reported)	885 (52%)	488 (57%)	974 (66%)
Missing	51 (3%)	51 (6%)	123 (8%)
Returned for the first follow-up <sup>2</sup>	950 (68%)	644 (87%)	1113 (76%)
Adherence to nPEP treatment (missing <4 pills) <sup>2</sup>	880 (63%)	557 (75%)	/
Missing	483 (34%)	168 (22%)	/
Early termination of nPEP treatment <sup>2</sup>	33 (2%)	11 (1%)	/
Missing	461 (33%)	144 (19%)	/
Re-exposure to HIV during nPEP treatment <sup>2</sup>	12 (< 1%)	11 (1%)	/

<sup>&</sup>lt;sup>1</sup> These two variables represent the nPEP *only* participants' entire nPEP history and the *PEP-to-PrEP* participants' nPEP history before their first PrEP consultation at l'Actuel.

<sup>&</sup>lt;sup>2</sup> 303 nPEP *only* participants and 114 *PEP-to-PrEP* participants did not initiate nPEP and were thus excluded from the analysis.

<sup>&</sup>lt;sup>3</sup> First follow-up: 4 weeks after the first nPEP consultation or 30 days after first PrEP consultation.

<sup>&</sup>lt;sup>4</sup> Abbreviations: (1) PEP: post-exposure prophylaxis; (2) PrEP: pre-exposure prophylaxis; (3) STI: sexually transmitted infection.

**Table 2.** Univariable and multivariable hazard ratios and 95% confidence interval (95%CI) from Cox proportional hazard models of the determinants of time to PrEP consultation among gay, bisexual, and other men who have sex with men (gbMSM) who used nPEP after January 2013 at the *Clinique médicale l'Actuel*.

Determinants	Univariate analysis (N=2,571)		Multivariate analysis (N=2,571)	
	Hazard ratio	95%CI	Hazard ratio	95%CI
Age (years)				
< 25	REF		REF	
25 - 49	1.61	[1.31, 1.98]	1.33	[1.08, 1.65]
≥ 50	1.47	[1.11, 1.95]	1.08	[0.81, 1.44]
Education <sup>1</sup>				
Secondary	RE	F	F	REF
College	1.01	[0.77, 1.31]	0.96	[0.73, 1.27]
University	1.24	[0.98, 1.56]	1.04	[0.82, 1.32]
Total number of nPEP episodes	1.34	[1.25, 1.44]	1.39	[1.31, 1.46]
Chemsex during the risk period related to PEPconsultations	1.23	[1.02, 1.49]	1.30	[1.08, 1.56]
Self-reported lifetime STI history <sup>1</sup>	1.54	[1.34, 1.77]	1.46	[1.26, 1.69]
Return for the first nPEP follow-up visit <sup>1</sup>	3.09	[2.49, 3.83]	3.36	[2.71, 4.16]

<sup>&</sup>lt;sup>1</sup> Due to missing values, education, self-reported lifetime STI history and return for the first follow-up visit were imputed using 5 multiple imputations. Pooled estimates based on Rubin's rules are shown in the table.

<sup>&</sup>lt;sup>2</sup> Abbreviations: (1) PEP: post-exposure prophylaxis; (2) STI: sexually transmitted infection.











